Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma

• Published in: Biomolecules (Basel, Switzerland) Vol. 13; no. 3; p. 538
• Main Authors: Sandhu, Yuuki, Harada, Norihiro, Sasano, Hitoshi, Harada, Sonoko, Ueda, Shoko, Takeshige, Tomohito, Tanabe, Yuki, Ishimori, Ayako, Matsuno, Kei, Abe, Sumiko, Nagaoka, Tetsutaro, Ito, Jun, Chiba, Asako, Akiba, Hisaya, Atsuta, Ryo, Izuhara, Kenji, Miyake, Sachiko, Takahashi, Kazuhisa
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.03.2023; MDPI
• Subjects: Adrenal Cortex Hormones - therapeutic use; Anaphylaxis; Anti-Asthmatic Agents - therapeutic use; Antibodies; Asthma; Asthma - drug therapy; benralizumab; Biological products; Biomarkers; Disease Progression; Double-Blind Method; Drug therapy; FeNO; Flow cytometry; Health aspects; Helper cells; Humans; Immunoregulation; Leukocytes (eosinophilic); Lymphocytes T; Nitric oxide; Patient outcomes; Patients; Peripheral blood; Precision medicine; Quality of Life; real-world setting; Steroids; T cells; Th17 Cells; Japan; United States > US; FeNO; asthma; real-world setting; benralizumab; Th17 cells

Benralizumab treatment reduces exacerbations and improves symptom control and quality of life in patients with severe eosinophilic asthma. However, the determination of biomarkers that predict therapeutic effectiveness is required for precision medicine. Herein, we elucidated the dynamics of various...